Biofrontera Inc.: updates and filings

BFRINASDAQHealthcare · Pharmaceutical Preparations

Price

$0.60

November 18, 2026Market cap $11M

What Ploutos Investor adds for Biofrontera

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 6 fiscal years, from 2020
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 86 daysAround Feb 12, 2027 · for Q4 2026

last Nov 13, 2026next Feb 12, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 19, 2026 latest annualNov 13, 2026 latest quarterly
  • Nov 13, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 13, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 13, 2026Results of operations
    Form8-K
  • Oct 30, 2026One of its securities removed from an exchange (usually a matured note)
    Form25-NSE
  • Sep 14, 2026Other material events
    Form8-K
  • Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 13, 2026Results of operations
    Form8-K
  • Aug 12, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jul 22, 2026Shares registered for employees
    FormS-8
  • Jul 22, 2026Annual report (amendment)for the period to Dec 31, 2025
    Form10-K/A
  • Jun 17, 2026Shareholder vote
    Form8-K
  • May 14, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 14, 2026Results of operations
    Form8-K
  • Apr 30, 2026Annual meeting proxy statement
    FormDEF 14A
  • Mar 19, 2026Annual reportfor the period to Dec 31, 2025
    Form10-K
  • Mar 19, 2026Results of operations
    Form8-K
  • Mar 9, 2026Regulation FD disclosure
    Form8-K
  • Feb 26, 2026Other material events
    Form8-K
  • Feb 11, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Feb 9, 2026Regulation FD disclosure
    Form8-K
  • Jan 28, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jan 13, 2026Results of operations
    Form8-K
  • Jan 7, 2026Delisting notice
    Form8-K
  • Dec 19, 2025Filing
    FormEFFECT
  • Dec 17, 2025Correspondence with the SEC
    FormCORRESP

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since May 7, 2021.

The full analysis

What do Biofrontera's filings show?

The filings are where every one of Biofrontera's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.